1. Background {#sec0005}
=============

Multiple in vitro RT-qPCR diagnosis kits are available on the market for the detection of SARS-CoV-2. Some of them have received emergency use authorization (EUA) from the U.S. Food & Drug Administration (FDA) while others only report validations made by manufacturers, and in general little is known about their performances using clinical specimens. The CDC designed 2019-nCoV CDC EUA kit (IDT, USA) is based on N1 and N2 probes to detect SARS-CoV-2 that have received positive evaluation on recent reports \[[@bib0005], [@bib0010], [@bib0015]\], and and RNase P as an RNA extraction quality control. Other kit avalaible in the market is nCoV-QS (MiCo BioMed; South Corea) that include probes \"ORF3a\" and \"N\" probes for SARS-CoV-2 detection but no probe for RNA extraction quality control, with no EUA approval neither from FDA (USA) nor from Korean CDC \[[@bib0020], [@bib0025], [@bib0030]\].

2. Objective {#sec0010}
============

This study compared the performance in terms of positive percent agreement (PPA) of nCoV-QS (MiCo BioMed; South Corea) and 2019-nCoV CDC EUA kit (IDT, USA) primers and probes for SARS-CoV-2 qPCR diagnosis from nasopharyngeal samples.

3. Study design {#sec0015}
===============

Fifty-four (54) clinical specimens (nasopharyngeal swabs collected on 0.5 mL TE pH 8 buffer) from patients selected as suspicious for SARS-CoV-2 infection were included on this study during the surveillance in Galapagos Islands started on April 8th 2020. Also, six negative controls (TE pH 8 buffer) were included as control for carryover contamination. Both CoV-QS and 2019-nCoV CDC EUA kits were used at SARS-CoV-2 diagnosis laboratory \"LabGal\" at \"Agencia de Regulación y Control de la Bioseguridad y Cuarentena para Galápagos\" at Puerto Ayora in Galapagos Islands (Ecuador), where we considered this validation necessary to guarantee the sensibility of SARS-CoV-2 during the surveillance.

4. Results {#sec0020}
==========

Twenty-five (25) samples were tested following an adapted version of the CDC protocol \[[@bib0005]\] using CFX96 BioRad instrument and PureLink Viral RNA/DNA Mini Kit (Invitrogen, USA) as an alternate RNA extraction method, and also interpreting as positive 3 samples where a probe was positive with Ct\<40 and the second one with Ct values up to 41.15 (See [Table 1](#tbl0005){ref-type="table"} and [Table 2](#tbl0010){ref-type="table"} a). We performed this protocol for both nCoV-QS and 2019-nCoV CDC EUA primers and probes kits. Nine samples were negative for both kits; Sixteen samples were positive for 2019-nCoV CDC EUA (range of Ct values: 23.02--41.15 for N1; 24.08--40.12 for N2), but only ten (PPA 62.5 %; p \< 0.001) of those ones were positive for nCoV-QS (range of Ct values: 28.71--39.98 for ORF3a; 24.48--35.44 for N). Results are detailed on [Table 1](#tbl0005){ref-type="table"}a. The assay was validated to detect less than 10 viral RNA copies/uL by using 2019-nCoV N positive control (IDT, USA).Table 1Performance of nCoV-QS compared to 2019-nCoV CDC EUA for RT-qPCR SARS-CoV-2 diagnosis (% values: PPA).Table 1CDC Probes SARS CoV-2 PositiveCDC Probes SARS CoV-2 NegativeVeri-Q Probes\
SARS CoV-2 Positive22 (66.7 %)0Veri-Q Probes\
SARS CoV-2 Negative1121Table 2Ct values for nCoV-QS and 2019-nCoV CDC EUA RT-qPCR using CDC adapted protocol for 25 samples (a) and MiCoBioMed protocol for 29 samples (b).Table 2SampleConc. \[copies/μL\]CT (2019-nCoV CDC EUA)Result (2019-nCoV CDC EUA)CT (nCoV-QS)Result (nCoV-QS)N1N2RPORF3aN1193453.323.0224.825.04Positive28.7224.48Positive2151418.723.3425.1622.69Positive32.1924.63Positive328204.025.5328.0226.11Positive30.7827.3Positive47157.327.3129.8225.43Positive34.7630.31Positive5699.330.3433.2325.32Positive37.2932.25Positive6684.130.3733.325.29PositiveN/A33.58Positive7657.430.4232.3729.23Positive38.2632.16Positive8261.631.6233.7627.32Positive39.8833.67Positive9236.531.7534.421.73Positive39.9834.24Positive10162.432.2434.8723.17Positive30.0435.44Positive1115.235.3337.4726.37PositiveN/AN/ANegative129.036.0140.0924.87PositiveN/AN/ANegative132.837.5339.6225.27PositiveN/AN/ANegative141.738.240.1226.97PositiveN/AN/ANegative151.238.5839.9927.74PositiveN/AN/ANegative160.241.1539.5127.98PositiveN/AN/ANegative17N/AN/AN/A23.11NegativeN/AN/ANegative18N/AN/AN/A26.6NegativeN/AN/ANegative19N/AN/AN/A25.56NegativeN/AN/ANegative20N/AN/AN/A25.12NegativeN/AN/ANegative21N/AN/AN/A25.26NegativeN/AN/ANegative22N/AN/AN/A27.63NegativeN/AN/ANegative23N/AN/AN/A26.35NegativeN/AN/ANegative24N/AN/AN/A25.6NegativeN/AN/ANegative25N/AN/AN/A27.77NegativeN/AN/ANegativeSampleConc. \[copies/μL\]CT (2019-nCoV CDC EUA)Result (2019-nCoV CDC EUA)CT (nCoV-QS)Result (nCoV-QS)N1N2RPORF3aN1883226.723.122.9624.14Positive27.1124.03Positive2736560.023.3123.3927.04Positive27.5124.39Positive3153530.725.0724.9728.66Positive29.1626.22Positive423205.627.227.4827.63Positive31.2228.19Positive54244.529.1129.227.07Positive33.6529.76Positive61886.730.0230.8829.81Positive34.2330.84Positive71706.630.1530.1732.26Positive32.0230.46Positive81573.930.1330.1231.17Positive32.2630.53Positive9719.531.131.226.25Positive35.431.03Positive10176.032.6932.7724.04Positive26.4531.87Positive11143.532.832.3631.46Positive35.0932.81Positive1251.634.0734.5126.56Positive39.4339.89Positive1340,334.3535.3924.38PositiveN/AN/ANegative143.337.1737.4326.51PositiveN/AN/ANegative151.837.8738.2730.89PositiveN/AN/ANegative161.637.6337.6229.84PositiveN/AN/ANegative170.639.0538.827.27PositiveN/AN/ANegative18N/AN/AN/A28.25NegativeN/AN/ANegative19N/AN/AN/A27.07NegativeN/AN/ANegative20N/AN/AN/A30.45NegativeN/AN/ANegative21N/AN/AN/A30.65NegativeN/AN/ANegative22N/AN/AN/A27.92NegativeN/AN/ANegative23N/AN/AN/A29.59NegativeN/AN/ANegative24N/AN/AN/A29.09NegativeN/AN/ANegative25N/AN/AN/A30.16NegativeN/AN/ANegative26N/AN/AN/A30.19NegativeN/AN/ANegative27N/AN/AN/A30.76NegativeN/AN/ANegative28N/AN/AN/A31.06NegativeN/AN/ANegative29N/AN/AN/A33.76NegativeN/AN/ANegative

Twenty-nine (29) samples were tested following instructions manual from MiCo BioMed for nCoV-QS kit \[[@bib0030]\], using MiCo BioMed One RT-qPCR kit. PureLink Viral RNA/DNA Mini Kit (Invitrogen, USA) was used for RNA extraction. We performed this protocol for both nCoV-QS and 2019-nCoV CDC EUA primers and probes kits. Twelve samples were negative for both kits; Seventeen samples were positive for 2019-nCoV CDC EUA (range of Ct values: 23.1--39.05 for N1; 22.96--38.8 for N2), but only 12 (PPA 70.5 %; p \< 0.001) of those ones were positive for nCoV-QS (range of Ct values: 26.45--39.43 for ORF3a; 24.03--39.89 for N). Results are detailed on [Table 1 and Table 2](#tbl0005){ref-type="table"}b. We used CFX96 BioRad to run qPCR but also results were confirmed using Veri-Q PCR316 instrument from MiCo BioMed \[[@bib0020]\]. The assay sensitivity indicated on manufacturers manual (1.8 copies/uL for OFR3a and 4.24 copies/uL for N) could not be validated because positive control concentration was not provided.

In summary, overall PPA for nCoV-QS was 66.7 % (22 out of 33 positives samples for 2019-nCoV CDC EUA; p \< 0.001), and 70.5 % and 62.5 % for MiCo BioMed and adapted CDC protocols, respectively. Additionally, considering the viral loads calculated following adapted CDC protocol with 2019-nCoV N positive control (IDT, USA), the limit of detection (viral copies/uL) for nCoV-QS kit is much higher than the one indicated at manufacturer\'s manual \[[@bib0030]\].

5. Discussion {#sec0025}
=============

Although the main limitation of our study is the sample size (54 specimens), our results support that nCoV-QS kit had a significant lower performance in terms on PPA and sensitivity compared to 2019-nCoV CDC EUA. Also, the lack of any probe for RNA extraction quality control like RNase P and the unreported concentration of positive controls provided for the kit that does not allow viral load calculations, are limitations to be considered when using nCoV-QS kit.

Considering the worldwide high demand of reagents for SARS-CoV RT-qPCR diagnosis, supplies shortage is a fact, actually affecting harder to developing countries like Ecuador. Under this scenario, validation studies are helpful to guarantee the quality of the supplies in the market for every country in the world.
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